MEDAG promotes breast cancer cell proliferation, pro-metastasis, and EMT through the AKT/AMPK/mTOR pathway and reduces epirubicin sensitivity in breast cancer cells via AKT/AMPK. The gene discussed is AKT1; the disease is breast carcinoma.